Activity
| Date | Panel | Item | Activity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
6 actions
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary immunodeficiency or monogenic inflammatory bowel disease v8.23 | AMFR | Arina Puzriakova changed review comment from: Comment on list classification: Rating Red as currently there is only a single human case report linking this gene to immune dysfunction. Also unaffected carriers call into question the association but good functional work. Additional cases required to ascertain pathogenicity.; to: Comment on list classification: Rating Red as currently there is only a single human case report linking this gene to immune dysfunction (PMID:38277122). Also unaffected carriers call into question the association but good functional work. Additional cases required to ascertain pathogenicity. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary immunodeficiency or monogenic inflammatory bowel disease v8.23 | AMFR | Arina Puzriakova changed review comment from: Comment on list classification: Rating Red as currently there is only a single report linking this gene to immune dysfunction. Also unaffected carriers call into question the association but good functional work. Additional cases required to ascertain pathogenicity.; to: Comment on list classification: Rating Red as currently there is only a single human case report linking this gene to immune dysfunction. Also unaffected carriers call into question the association but good functional work. Additional cases required to ascertain pathogenicity. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary immunodeficiency or monogenic inflammatory bowel disease v8.23 | AMFR | Arina Puzriakova Classified gene: AMFR as Red List (low evidence) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary immunodeficiency or monogenic inflammatory bowel disease v8.23 | AMFR | Arina Puzriakova Added comment: Comment on list classification: Rating Red as currently there is only a single report linking this gene to immune dysfunction. Also unaffected carriers call into question the association but good functional work. Additional cases required to ascertain pathogenicity. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary immunodeficiency or monogenic inflammatory bowel disease v8.23 | AMFR | Arina Puzriakova Gene: amfr has been classified as Red List (Low Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary immunodeficiency or monogenic inflammatory bowel disease v4.163 | AMFR |
Boaz Palterer gene: AMFR was added gene: AMFR was added to Primary immunodeficiency or monogenic inflammatory bowel disease. Sources: Literature Mode of inheritance for gene: AMFR was set to MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown Publications for gene: AMFR were set to 38277122 Phenotypes for gene: AMFR were set to Severe VZV; Varicella; HLH; Hemophagocytic lymphohistyocytosis Penetrance for gene: AMFR were set to Incomplete Review for gene: AMFR was set to RED Added comment: 1 patient from one kindred with severe disseminated VZV and HLH, incomplete penetrance as mother and siblings are not affected. Extensive functional ex-vivo and in-vitro data. Sources: Literature |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||